Sarepta Therapeutics Financials - Benzinga

Sarepta Therapeutics Inc

SRPTNASDAQ

Trade with Public

Trade with Public

$18.95

-1.86-8.94%

À la clôture: Sep 23, 5:00 PM EST

$19.01

0.060.32%

Après les heures: 7:48 PM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Sarepta Therapeutics Financials

Sarepta Therapeutics (SRPT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings of $2.02 per share

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Sarepta Therapeutics Q1 Adj. EPS $3.16 Beats $0.99 Estimate, Sales $730.803M Beat $474.155M Estimate

Benzinga Newsdesk

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.

Vandana Singh

PRO
Sarepta Therapeutics Q4 Adj. EPS $(3.58) Misses $(1.31) Estimate, Sales $442.934M Beat $391.924M Estimate

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the analyst consensus estimate of $(1.31) by 172.45 percent. This is a 288.42 percent decrease over earnings of $1.90 per

Benzinga Newsdesk

Earnings Scheduled For February 25, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved